Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488

          

Clinical Trial News

Provectus Biopharmaceuticals begins recruitment for phase 2 mechanism of action clinical trial of PH-10 for psoriasis

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company ("Provectus"), has announced that it has opened recruitment for its phase 2 mechanism of...

Expensive Parkinson's drugs may produce 'bigger placebo effect'

A placebo effect from higher expectations for a drug's efficacy is greater if people with Parkinson's disease are told the injection is more expensive, a controlled study suggests.

Phase I/II clinical trial in second-line lower risk myelodysplastic syndrome with OPN-305 initiated

Opsona Therapeutics Ltd, the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune, inflammatory diseases and oncology, announces that it has initiated...

ESMO delivers on dynamic force strategy to improve cancer research in Europe

The European Society for Medical Oncology (ESMO) has created a new website section dedicated to research funding opportunities as part of its new determination to be 'a dynamic force of forward...

The challenges of sharing of clinical trial data

Transparency and sharing of information from clinical trials has been gathering support from industry, the government, researchers, and medical journals.

Vascular Flow Technologies announces new Haemodialysis Access study

Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar FlowTM (SLFTM) technology to replicate natural blood flow for enhanced patient outcomes,has announced the...

Dry eye syndrome: Neuroptis successfully completes the pre-clinical phase for ML7

Neuroptis, a company specialized in the development of drugs to treat eye disorders, has announced positive results from a second animal trial of its preservative-free ML7 eye drops.

First evidence of potential efficacy of Tau Aggregation Inhibitor therapy in Alzheimer's disease

The Journal of Alzheimer's Disease has published the results of the first clinical trial of a Tau Aggregation Inhibitor (TAI) in Alzheimer's disease (AD).



James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook